The tyrphostin agent AG490 prevents and reverses type 1 diabetes in NOD mice.
Recent studies in the NOD (non-obese diabetic) mouse model of type 1 diabetes (T1D) support the notion that tyrosine kinase inhibitors have the potential for modulating disease development. However, the therapeutic effects of AG490 on the development of T1D are unknown.Female NOD mice were treated w...
| Main Authors: | , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Public Library of Science (PLoS)
2012-01-01
|
| Series: | PLoS ONE |
| Online Access: | http://europepmc.org/articles/PMC3351395?pdf=render |
| _version_ | 1818668848573841408 |
|---|---|
| author | Abdoreza Davoodi-Semiromi Clive H Wasserfall Chang Qing Xia Rhonda M Cooper-DeHoff Martin Wabitsch Michael Clare-Salzler Mark Atkinson |
| author_facet | Abdoreza Davoodi-Semiromi Clive H Wasserfall Chang Qing Xia Rhonda M Cooper-DeHoff Martin Wabitsch Michael Clare-Salzler Mark Atkinson |
| author_sort | Abdoreza Davoodi-Semiromi |
| collection | DOAJ |
| description | Recent studies in the NOD (non-obese diabetic) mouse model of type 1 diabetes (T1D) support the notion that tyrosine kinase inhibitors have the potential for modulating disease development. However, the therapeutic effects of AG490 on the development of T1D are unknown.Female NOD mice were treated with AG490 (i.p, 1 mg/mouse) or DMSO starting at either 4 or 8 week of age, for five consecutive week, then once per week for 5 additional week. Analyses for the development and/or reversal of diabetes, insulitis, adoptive transfer, and other mechanistic studies were performed.AG490 significantly inhibited the development of T1D (p = 0.02, p = 0.005; at two different time points). Monotherapy of newly diagnosed diabetic NOD mice with AG490 markedly resulted in disease remission in treated animals (n = 23) in comparision to the absolute inability (0%; 0/10, p = 0.003, Log-rank test) of DMSO and sustained eugluycemia was maintained for several months following drug withdrawal. Interestingly, adoptive transfer of splenocytes from AG490 treated NOD mice failed to transfer diabetes to recipient NOD.Scid mice. CD4 T-cells as well as bone marrow derived dendritic cells (BMDCs) from AG490 treated mice, showed higher expression of Foxp3 (p<0.004) and lower expression of co-stimulatory molecules, respectively. Screening of the mouse immune response gene arrary indicates that expression of costimulaotry molecule Ctla4 was upregulated in CD4+ T-cell in NOD mice treated with AG490, suggesting that AG490 is not a negative regulator of the immune system.The use of such agents, given their extensive safety profiles, provides a strong foundation for their translation to humans with or at increased risk for the disease. |
| first_indexed | 2024-12-17T06:42:50Z |
| format | Article |
| id | doaj.art-c80d468084604c89aa275bcd47a6c83e |
| institution | Directory Open Access Journal |
| issn | 1932-6203 |
| language | English |
| last_indexed | 2024-12-17T06:42:50Z |
| publishDate | 2012-01-01 |
| publisher | Public Library of Science (PLoS) |
| record_format | Article |
| series | PLoS ONE |
| spelling | doaj.art-c80d468084604c89aa275bcd47a6c83e2022-12-21T21:59:48ZengPublic Library of Science (PLoS)PLoS ONE1932-62032012-01-0175e3607910.1371/journal.pone.0036079The tyrphostin agent AG490 prevents and reverses type 1 diabetes in NOD mice.Abdoreza Davoodi-SemiromiClive H WasserfallChang Qing XiaRhonda M Cooper-DeHoffMartin WabitschMichael Clare-SalzlerMark AtkinsonRecent studies in the NOD (non-obese diabetic) mouse model of type 1 diabetes (T1D) support the notion that tyrosine kinase inhibitors have the potential for modulating disease development. However, the therapeutic effects of AG490 on the development of T1D are unknown.Female NOD mice were treated with AG490 (i.p, 1 mg/mouse) or DMSO starting at either 4 or 8 week of age, for five consecutive week, then once per week for 5 additional week. Analyses for the development and/or reversal of diabetes, insulitis, adoptive transfer, and other mechanistic studies were performed.AG490 significantly inhibited the development of T1D (p = 0.02, p = 0.005; at two different time points). Monotherapy of newly diagnosed diabetic NOD mice with AG490 markedly resulted in disease remission in treated animals (n = 23) in comparision to the absolute inability (0%; 0/10, p = 0.003, Log-rank test) of DMSO and sustained eugluycemia was maintained for several months following drug withdrawal. Interestingly, adoptive transfer of splenocytes from AG490 treated NOD mice failed to transfer diabetes to recipient NOD.Scid mice. CD4 T-cells as well as bone marrow derived dendritic cells (BMDCs) from AG490 treated mice, showed higher expression of Foxp3 (p<0.004) and lower expression of co-stimulatory molecules, respectively. Screening of the mouse immune response gene arrary indicates that expression of costimulaotry molecule Ctla4 was upregulated in CD4+ T-cell in NOD mice treated with AG490, suggesting that AG490 is not a negative regulator of the immune system.The use of such agents, given their extensive safety profiles, provides a strong foundation for their translation to humans with or at increased risk for the disease.http://europepmc.org/articles/PMC3351395?pdf=render |
| spellingShingle | Abdoreza Davoodi-Semiromi Clive H Wasserfall Chang Qing Xia Rhonda M Cooper-DeHoff Martin Wabitsch Michael Clare-Salzler Mark Atkinson The tyrphostin agent AG490 prevents and reverses type 1 diabetes in NOD mice. PLoS ONE |
| title | The tyrphostin agent AG490 prevents and reverses type 1 diabetes in NOD mice. |
| title_full | The tyrphostin agent AG490 prevents and reverses type 1 diabetes in NOD mice. |
| title_fullStr | The tyrphostin agent AG490 prevents and reverses type 1 diabetes in NOD mice. |
| title_full_unstemmed | The tyrphostin agent AG490 prevents and reverses type 1 diabetes in NOD mice. |
| title_short | The tyrphostin agent AG490 prevents and reverses type 1 diabetes in NOD mice. |
| title_sort | tyrphostin agent ag490 prevents and reverses type 1 diabetes in nod mice |
| url | http://europepmc.org/articles/PMC3351395?pdf=render |
| work_keys_str_mv | AT abdorezadavoodisemiromi thetyrphostinagentag490preventsandreversestype1diabetesinnodmice AT clivehwasserfall thetyrphostinagentag490preventsandreversestype1diabetesinnodmice AT changqingxia thetyrphostinagentag490preventsandreversestype1diabetesinnodmice AT rhondamcooperdehoff thetyrphostinagentag490preventsandreversestype1diabetesinnodmice AT martinwabitsch thetyrphostinagentag490preventsandreversestype1diabetesinnodmice AT michaelclaresalzler thetyrphostinagentag490preventsandreversestype1diabetesinnodmice AT markatkinson thetyrphostinagentag490preventsandreversestype1diabetesinnodmice AT abdorezadavoodisemiromi tyrphostinagentag490preventsandreversestype1diabetesinnodmice AT clivehwasserfall tyrphostinagentag490preventsandreversestype1diabetesinnodmice AT changqingxia tyrphostinagentag490preventsandreversestype1diabetesinnodmice AT rhondamcooperdehoff tyrphostinagentag490preventsandreversestype1diabetesinnodmice AT martinwabitsch tyrphostinagentag490preventsandreversestype1diabetesinnodmice AT michaelclaresalzler tyrphostinagentag490preventsandreversestype1diabetesinnodmice AT markatkinson tyrphostinagentag490preventsandreversestype1diabetesinnodmice |